AMISTAD II: Study Design 2,118 patients with anterior infarction, double blind randomized trial High Dose Adenosine 70 µg/kg/min for 3 hours Low Dose Adenosine 50 µg/kg/min for 3 hours Placebo + + + Thrombolysis or PCI Thrombolysis or PCI Thrombolysis or PCI Infarct Size 120 –168 hours Death/CHF at 6 months

AMISTAD II: Primary Endpoint All Patients Reperfusion Success Reperfusion Failure P=0.043 P=NS P=NS Death/CHF at 6 months (%) Death/CHF at 6 months (%) Adenosine Pooled Adenosine High Dose Placebo Adenosine Placebo Adenosine Placebo

AMISTAD II: Primary Endpoint by Time from Symptom Onset < 2 Hours 2 - 4 Hours > 4 Hours Death/CHF at 6 months (%) Adenosine Placebo Adenosine Placebo Adenosine Placebo

AMISTAD II: Infarct Size P=0.078 P=0.028 Adenosine Pooled Adenosine High Dose Adenosine Low Dose Placebo